While we were interested in the impact that ABL1 inhibition has in the therapeutic effect of imatinib in GIST, these authors investigated the impact of KIT inhibition on the therapeutic effect of BCR-ABL1 inhibition by imatinib in CML [28]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.